These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3899669)

  • 1. Effect of pinacidil on blood pressure, plasma catecholamines and plasma renin activity in essential hypertension.
    Muiesan G; Fariello R; Muiesan ML; Christensen OE
    Eur J Clin Pharmacol; 1985; 28(5):495-9. PubMed ID: 3899669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, randomized, controlled trial comparing pinacidil to hydralazine in essential hypertension.
    Byyny RL; Nies AS; LoVerde ME; Mitchell WD
    Clin Pharmacol Ther; 1987 Jul; 42(1):50-7. PubMed ID: 3297468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous pinacidil in the acute treatment of hypertension.
    Rijk MC; Thien T
    J Clin Pharmacol; 1987 Jul; 27(7):468-74. PubMed ID: 3308975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between blood pressure, heart rate and plasma epinephrine, norepinephrine, angiotensin II concentrations, plasma renin activity during chronic guanfacine therapy in patients with essential arterial hypertension.
    Collart F; Staroukine M; Verniory A
    Acta Cardiol; 1985; 40(3):269-76. PubMed ID: 3895792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure, heart rate, catecholamines and plasma renin activity following institution and withdrawal of guanfacine treatment in moderate hypertension.
    Manhem P; Hökfelt B
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):109S-114S. PubMed ID: 6994763
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative effects of pinacidil and prazosin on blood pressure, weight, plasma volume, the renin-angiotensin-aldosterone system, and the renal kallikrein-kinin system in patients with essential hypertension.
    Solomon RJ; Weinberg MS
    J Clin Hypertens; 1987 Dec; 3(4):589-95. PubMed ID: 3330989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pinacidil with and without hydrochlorothiazide. Dose-response relationships from results of a 4 x 3 factorial design study.
    Goldberg MR; Offen WW
    Drugs; 1988; 36 Suppl 7():83-92. PubMed ID: 3076140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of antihypertensive, renal hemodynamic, and humoral effects of pinacidil and hydralazine monotherapy.
    Abraham PA; Halstenson CE; Matzke GR; Keane WF
    J Clin Hypertens; 1987 Dec; 3(4):439-51. PubMed ID: 3330986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels.
    Goldberg MR
    J Cardiovasc Pharmacol; 1988; 12 Suppl 2():S41-7. PubMed ID: 2466178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension.
    Goldberg MR; Rockhold FW; Offen WW; Dornseif BE
    Clin Pharmacol Ther; 1989 Aug; 46(2):208-18. PubMed ID: 2758730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive efficacy of pinacidil--automatic ambulatory blood pressure monitoring.
    Zachariah PK; Sheps SG; Schirger A; Fisher LD; Shub C; Collins JB; Spiekerman RE
    Eur J Clin Pharmacol; 1986; 31(2):133-41. PubMed ID: 3803413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catecholamines and the renin-angiotensin-aldosterone system during treatment with felodipine ER or hydrochlorothiazide in essential hypertension.
    Koenig W; Binner L; Gabrielsen F; Sund M; Rosenthal J; Hombach V
    J Cardiovasc Pharmacol; 1991 Sep; 18(3):349-53. PubMed ID: 1720834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effects of prizidilol on blood pressure, heart rate, catecholamines, renin and aldosterone in essential hypertension.
    Bianchetti MG; Boehringer K; Weidmann P; Link L; Schiffl H; Ziegler WH
    Eur J Clin Pharmacol; 1982 Oct; 23(4):289-96. PubMed ID: 6129141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antihypertensive effect of pinacidil versus prazosin in mild to moderate hypertensive patients seen in general practice.
    Sterndorff B; Johansen P
    Acta Med Scand; 1988; 224(4):329-36. PubMed ID: 3188983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator.
    Breen EG; Mulhall D; Keogh JA
    Eur J Clin Pharmacol; 1985; 28(4):381-6. PubMed ID: 4029244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.
    Friedel HA; Brogden RN
    Drugs; 1990 Jun; 39(6):929-67. PubMed ID: 2196168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension.
    D'Arcy V; Laher M; McCoy D; Sullivan P; Walsh CH; Hickey MP
    Eur J Clin Pharmacol; 1985; 28(3):347-9. PubMed ID: 4007040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of long-term treatment of essential hypertension with guanfacine.
    Higuchi M; Overlack A; Stumpe KO
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):61S-64S. PubMed ID: 6994780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative trial of pinacidil versus prazosin in mild to moderate arterial hypertension.
    Sterndorff B; Johansen P
    Drugs; 1988; 36 Suppl 7():64-6. PubMed ID: 3076137
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of combined therapy with amiloride and hydrochlorothiazide on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in hypertensive patients.
    Svendsen UG; Ibsen H; Rasmussen S; Leth A; Nielsen MD; Dige-Petersen H; Giese J
    Eur J Clin Pharmacol; 1986; 30(2):151-6. PubMed ID: 3519243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.